Molecular structure of Baricitinib, CAS Number: 1187594-09-7
Baricitinib (CAS 1187594-09-7)
Alternate Names:
INCB28050; LY3009104; 2-[1-ethylsulfonyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile
Application:
Baricitinib is a selective inhibitor of JAK1 and JAK2
CAS Number:
1187594-09-7
Molecular Weight:
371.42
Molecular Formula:
C16H17N7O2S
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Baricitinib, also known as INCB028050 or LY3009104, is a selective JAK1 and JAK2 inhibitor with nanomolar potency against JAK1 (5.9 nM) and JAK2 (5.7 nM). Baricitinib enzymes are involved in the regulation of immune responses, and Baricitinib is able to block their activity, thus reducing inflammation. It has also been shown to reduce the production of pro-inflammatory cytokines, such as TNF-α, IL-6, and IL-1β. Baricitinib has anti-inflammatory, immunomodulatory, anti-tumor, anti-viral, and anti-bacterial activities.
Baricitinib (CAS 1187594-09-7) References
- Baricitinib: First Global Approval. | Markham, A. 2017. Drugs. 77: 697-704. PMID: 28290136
- Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials. | Simpson, EL., et al. 2020. Br J Dermatol. 183: 242-255. PMID: 31995838
- Comparative efficacy and safety of tofacitinib, baricitinib, upadacitinib, filgotinib and peficitinib as monotherapy for active rheumatoid arthritis. | Ho Lee, Y. and Gyu Song, G. 2020. J Clin Pharm Ther. 45: 674-681. PMID: 32495356
- Efficacy and Safety of Tofacitinib, Baricitinib, and Upadacitinib for Rheumatoid Arthritis: A Systematic Review and Meta-Analysis. | Wang, F., et al. 2020. Mayo Clin Proc. 95: 1404-1419. PMID: 32499126
- Baricitinib: A Review of Pharmacology, Safety, and Emerging Clinical Experience in COVID-19. | Jorgensen, SCJ., et al. 2020. Pharmacotherapy. 40: 843-856. PMID: 32542785
- A real-world disproportionality analysis of FDA Adverse Event Reporting System (FAERS) events for baricitinib. | Peng, L., et al. 2020. Expert Opin Drug Saf. 19: 1505-1511. PMID: 32693646
- Baricitinib treatment resolves lower-airway macrophage inflammation and neutrophil recruitment in SARS-CoV-2-infected rhesus macaques. | Hoang, TN., et al. 2021. Cell. 184: 460-475.e21. PMID: 33278358
- JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib. | Traves, PG., et al. 2021. Ann Rheum Dis. 80: 865-875. PMID: 33741556
- Baricitinib: From Rheumatoid Arthritis to COVID-19. | Assadiasl, S., et al. 2021. J Clin Pharmacol. 61: 1274-1285. PMID: 33870531
- Baricitinib for the treatment of atopic dermatitis. | Melo, A., et al. 2022. J Dermatolog Treat. 33: 2404-2413. PMID: 34379541
- Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database. | Taylor, PC., et al. 2022. Ann Rheum Dis. 81: 335-343. PMID: 34706874
- Baricitinib for relapsing giant cell arteritis: a prospective open-label 52-week pilot study. | Koster, MJ., et al. 2022. Ann Rheum Dis. 81: 861-867. PMID: 35190385
- Baricitinib: A Review in Moderate to Severe Atopic Dermatitis. | Hoy, SM. 2022. Am J Clin Dermatol. 23: 409-420. PMID: 35503162
- Comparative efficacy and safety of abrocitinib, baricitinib, and upadacitinib for moderate-to-severe atopic dermatitis: A network meta-analysis. | Wan, H., et al. 2022. Dermatol Ther. 35: e15636. PMID: 35703351
- A Review of Safety Outcomes from Clinical Trials of Baricitinib in Rheumatology, Dermatology and COVID-19. | Bieber, T., et al. 2022. Adv Ther. 39: 4910-4960. PMID: 36063279
Inhibitor of:
4930558K02Rik, ARK-3, C-MIP, C1QTNF (C1q and TNF related), CD2BP2, CD3-ε, CTRP4, DCIR3, DEF6, DSCR 2, GBP3, GILT, IF3, IFI-16, IFI-202, IFIT2, IFIT3, IFN-α/βRα, IFN-α/βRβ, IFN-α1, IFN-α13, IFN-α2, IFN-α5, IFN-α6, IFN-αR, IFN-δ, IFN-γRα, IFN-γRβ, IgG, IL-10Rβ, IL-12Rβ2, IL-15, IL-20Rβ, IL-21R, IL-22Rα2, IL-28, IL-28R, IL-6, IL-7, Interferon (IFN), Interferon inducible (IFI, IFIT), IRF-8, JAK1, JAK2, JAKMIP2, JAKMIP3, JFC1, KSHV ORF 72, MsrB2, MUM1, NKG2-D, Olr307, Olr728, OTTMUSG00000007655, OTTMUSG00000011262, OTTMUSG00000011265, OTTMUSG00000011268, Pinch-2, Psoriasin, RAG-1, RT1-Db1, SOCS-4, SOCS-5, Spi-B, ST18, STC2, SYCE2, Trav6d-5, TRIL, Tyk 2, and V1RG3.Activator of:
CIS, ISGF-3γ p48, JAK1, Oas1c, and RELL2.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Baricitinib, 5 mg | sc-364730 | 5 mg | $200.00 | |||
Baricitinib, 25 mg | sc-364730A | 25 mg | $664.00 |